MCID: BLD087
MIFTS: 54

Bladder Cancer, Somatic malady

Categories: Genetic diseases (common), Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Cancer, Somatic

About this section

Aliases & Descriptions for Bladder Cancer, Somatic:

Name: Bladder Cancer, Somatic 50 23 12
Bladder Carcinoma 33 11 13 48
Bladder Cancer 68 48 36
Carcinoma of Bladder 11 66
Urothelial Carcinoma of the Bladder 68
 
Carcinoma of Urinary Bladder 11
Urinary Bladder Cancer 68
Cancer of the Bladder 25
Carcinoma Bladder 11
Blc 68

Characteristics:

HPO:

62
bladder cancer, somatic:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM50 109800
Disease Ontology11 DOID:4007
NCIt43 C4912
MedGen35 C0005684
MeSH37 D001749
ICD1028 C67

Summaries for Bladder Cancer, Somatic

About this section
MedlinePlus:36 The bladder is a hollow organ in your lower abdomen that stores urine. bladder cancer occurs in the lining of the bladder. it is the sixth most common type of cancer in the united states. symptoms include blood in your urine a frequent urge to urinate pain when you urinate low back pain risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. people with a family history of bladder cancer or who are older, white, or male have a higher risk. treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. biologic therapy boosts your body's own ability to fight cancer. nih: national cancer institute

MalaCards based summary: Bladder Cancer, Somatic, also known as bladder carcinoma, is related to papilloma and prostate cancer, and has symptoms including transitional cell carcinoma of the bladder An important gene associated with Bladder Cancer, Somatic is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways are Transcriptional activation of p53 responsive genes and MNAR-PELP1 and Estrogen Receptor Interaction. Affiliated tissues include testes, and related mouse phenotypes are hearing/vestibular/ear and craniofacial.

Disease Ontology:11 A urinary bladder cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

UniProtKB/Swiss-Prot:68 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Genetics Home Reference:24 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

Description from OMIM:50 109800

Related Diseases for Bladder Cancer, Somatic

About this section

Diseases related to Bladder Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 250)
idRelated DiseaseScoreTop Affiliating Genes
1papilloma31.0HRAS, KRAS, KRT20
2prostate cancer29.7CD44, CDH1, CDKN1A, ERBB2, EZH2, FGF2
3bladder carcinoma in situ12.1
4gall bladder carcinoma in situ11.8
5urinary bladder urothelial carcinoma11.2
6transitional cell carcinoma11.2
7urinary bladder cancer11.2
8epidermal nevus, somatic11.1FGFR3, HRAS, KRAS
9familial renal oncocytoma11.1FGFR3, TP53, UPK3A
10bladder cancer, childhood11.1
11vagina sarcoma11.1HRAS, KRAS
12oral tuberculosis11.1CDH1, TP53
13advanced sleep phase syndrome11.1HRAS, KRAS, TP53
14gastric adenocarcinoma11.1HRAS, KRAS, TP53
15salivary gland adenoid cystic carcinoma11.1CDKN2A, TP53
16gastric cancer risk after h. pylori infection11.1CDH1, GNL3, KRAS
17rectum mucinous adenocarcinoma11.1ERBB2, KRAS, TP53
18tabes dorsalis11.1HRAS, KRAS, KRT20
19migraine with aura11.1HRAS, KRAS, KRT20
20spindle epithelial tumor with thymus-like differentiation tumor11.1CDKN2A, HRAS, KRAS
21biliary papillomatosis11.1CDKN2A, TP53
22breast papillary carcinoma11.1ERBB2, HRAS, KRAS
23multidrug-resistant tuberculosis11.1FGFR3, RB1, TP53
24dermatosis papulosa nigra11.1ERBB2, HRAS, KRAS
25spastic ataxia 311.1CDKN2A, KRT20, TP53
26vulva basal cell carcinoma11.1CDH1, KRT20, TP53
27schimmelpenning-feuerstein-mims syndrome, somatic mosaic11.1FGFR3, GNL3, HRAS, KRAS
28pityriasis versicolor11.1CDKN2A, TP53, UPK2
29hypersensitivity reaction type iv disease11.1CDKN2A, FGFR3, TP53
30extrahepatic bile duct adenocarcinoma11.1CDH1, KRT20, TP53
31lateral sinus thrombosis11.1CDH1, KRAS, KRT20
32pituitary carcinoma11.1CDKN2A, ERBB2, TP53
33peptic ulcer disease11.1MKI67, TP53
34comedo carcinoma11.1CDH1, KRT20, UPK3A
35skeletal tuberculosis11.1CDKN2A, ERBB2
36scrapie11.1FGFR3, KRT20, TP53, UPK3A
37ovarian serous adenofibroma11.1HRAS, KRAS, KRT20, TP53
38cardiofaciocutaneous syndrome 211.1GNL3, KRAS
39intrahepatic bile duct adenoma11.1FGFR3, KRT20, TP53, UPK3A
40mesenchymoma11.0CDKN2A, KRT20, TP53
41ras-associated autoimmune leukoproliferative disorder11.0GNL3, KRAS
42ureter adenocarcinoma11.0CDKN2A, HRAS, KRAS, TP53
43adenofibroma11.0CDKN2A, HRAS, KRAS, TP53
44grade iii astrocytoma11.0CDKN2A, FGFR3, TP53
45epithelioid trophoblastic tumor11.0CDKN2A, KRT20, TP53
46hemangioma of lung11.0CDH1, HRAS, KRAS, TP53
47ovarian cancer, somatic11.0CDH1, ERBB2, KRAS
48asrar facharzt haque syndrome11.0CDKN2A, ERBB2, RB1
49periapical granuloma11.0CDH1, HRAS, KRAS, TP53
50cell type benign neoplasm11.0ERBB2, RASSF1, TP53

Graphical network of the top 20 diseases related to Bladder Cancer, Somatic:



Diseases related to bladder cancer, somatic

Symptoms for Bladder Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

109800

Clinical features from OMIM:

109800

HPO human phenotypes related to Bladder Cancer, Somatic:

id Description Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder HP:0006740

Drugs & Therapeutics for Bladder Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Valstar16 VALRUBICIN Anthra Pharmaceuticals October 1998
FDA Label: Valstar
Disease/s that Drug Treats:Bladder Cancer
Indications and Usage:16 VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of theurinary bladder in patients for whom immediate cystectomy would be associated withunacceptable morbidity or mortality.
DrugBank Targets:14 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:16 
Target: DNA topoisomerase II
Action: interferes with normal breaking-resealing action
FDA: Valrubicin is an anthracycline that affects a variety of inter-relatedbiological functions, most of which involve nucleic acid metabolism. It readily penetrates intocells, where it inhibits the incorporation of nucleosides into nucleic acids, causes extensivechromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly toDNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interferencewith the normal DNA breaking-resealing action of DNA topoisomerase II.

Drugs for Bladder Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FulvestrantPhase 2182129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
 
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
2
PaclitaxelPhase 2269133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
3
Pancrelipase91753608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
4pancreatin917

Interventional clinical trials:

idNameStatusNCT IDPhase
1An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene AmplificationRecruitingNCT01953926Phase 2
2Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruitingNCT01772771

Search NIH Clinical Center for Bladder Cancer, Somatic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer, Somatic:
Neo-Urinary Conduit
Embryonic/Adult Cultured Cells Related to Bladder Cancer, Somatic:
Neo-Urinary Conduit, PMID: 22136657

Genetic Tests for Bladder Cancer, Somatic

About this section

Genetic tests related to Bladder Cancer, Somatic:

id Genetic test Affiliating Genes
1 Bladder Carcinoma25
2 Bladder Cancer, Somatic23 FGFR3, HRAS, KRAS, RB1

Anatomical Context for Bladder Cancer, Somatic

About this section

MalaCards organs/tissues related to Bladder Cancer, Somatic:

34
Testes

Animal Models for Bladder Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Bladder Cancer, Somatic:

39 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537710.5CDKN1A, FGF2, FGFR3, KRAS, RB1, TP53
2MP:000538210.4CDKN1A, ERBB2, FGFR3, HRAS, KRAS, RB1
3MP:000537010.3CD44, CDKN1A, CDKN2A, KRAS, RASSF1, RB1
4MP:000301210.1CDH1, CDKN1A, CDKN2A, EZH2, FGFR3, HRAS
5MP:000538110.0CD44, CDH1, CDKN1A, CDKN2A, ERBB2, FGFR3
6MP:000538010.0CDH1, CDKN1A, CDKN2A, ERBB2, EZH2, GNL3
7MP:00053889.9CD44, CDKN1A, CDKN2A, ERBB2, FGFR3, GNL3
8MP:00107719.9CD44, CDH1, CDKN1A, CDKN2A, ERBB2, EZH2
9MP:00053699.9CD44, CDKN1A, CDKN2A, ERBB2, EZH2, FGF2
10MP:00053899.9CD44, CDH1, CDKN1A, CDKN2A, ERBB2, FGF2
11MP:00053919.9CD44, CDKN1A, CDKN2A, FGF2, FGFR3, KRAS
12MP:00028739.7CD44, CDH1, ERBB2, EZH2, FGFR3, HRAS
13MP:00053679.6CD44, CDKN1A, DAPK1, FGFR3, HRAS, KRAS
14MP:00020069.6CD44, CDH1, CDKN1A, CDKN2A, ERBB2, EZH2
15MP:00053719.6CD44, CDKN1A, ERBB2, FGFR3, KRAS, RB1
16MP:00053799.5CD44, CDH1, CDKN1A, CDKN2A, ERBB2, EZH2
17MP:00053849.5CD44, CDH1, CDKN1A, CDKN2A, DAPK1, ERBB2
18MP:00053859.5CD44, CDH1, CDKN1A, CDKN2A, ERBB2, EZH2
19MP:00036319.4CD44, CDKN1A, CDKN2A, DAPK1, ERBB2, EZH2
20MP:00053909.4CD44, CDKN1A, CDKN2A, ERBB2, EZH2, FGF2
21MP:00053789.3CD44, CDH1, CDKN1A, CDKN2A, ERBB2, EZH2
22MP:00053869.3CD44, CDKN1A, CDKN2A, DAPK1, ERBB2, EZH2
23MP:00107689.3CD44, CDH1, CDKN1A, CDKN2A, ERBB2, EZH2
24MP:00053768.8CD44, CDH1, CDKN1A, CDKN2A, DAPK1, ERBB2

Publications for Bladder Cancer, Somatic

About this section

Variations for Bladder Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer, Somatic:

68
id Symbol AA change Variation ID SNP ID
1FGFR3p.Arg248CysVAR_004148rs121913482
2FGFR3p.Ser249CysVAR_004149rs121913483
3FGFR3p.Gly370CysVAR_004151rs121913479
4FGFR3p.Lys650GluVAR_004160rs78311289
5FGFR3p.Lys650GlnVAR_018390rs78311289

Clinvar genetic disease variations for Bladder Cancer, Somatic:

5
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.34G> C (p.Gly12Arg)single nucleotide variantPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
2NM_005343.3(HRAS): c.35G> T (p.Gly12Val)single nucleotide variantPathogenicrs104894230GRCh37Chr 11, 534288: 534288
3RB1RB1, IVS20, A-G, -2single nucleotide variantPathogenic
4FGFR3NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)single nucleotide variantPathogenicrs121913483GRCh37Chr 4, 1803568: 1803568
5FGFR3NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln)single nucleotide variantPathogenicrs78311289GRCh37Chr 4, 1807889: 1807889
6TSC1NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter)single nucleotide variantPathogenicrs118203542GRCh37Chr 9, 135781440: 135781440
7TSC1NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter)single nucleotide variantPathogenicrs118203631GRCh37Chr 9, 135779172: 135779172

Cosmic variations for Bladder Cancer, Somatic:

8 (show all 47)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM44023TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.560G>Ap.G187D0
2COSM43778TP53urinary tract,bladder,carcinoma,adenocarcinomac.713G>Tp.C238F0
3COSM10790TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.455C>Tp.P152L0
4COSM10812TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.722C>Tp.S241F0
5COSM45297TP53urinary tract,bladder,carcinoma,adenocarcinomac.810T>Gp.F270L0
6COSM10648TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.524G>Ap.R175H0
7COSM10722TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.853G>Ap.E285K0
8COSM45285TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.795G>Cp.L265L0
9COSM763PIK3CAurinary tract,bladder,carcinoma,squamous cell carcinomac.1633G>Ap.E545K0
10COSM11073TP53urinary tract,bladder,carcinoma,adenocarcinomac.1024C>Tp.R342*0
11COSM45293TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.407A>Gp.Q136R0
12COSM10660TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.818G>Ap.R273H0
13COSM550KRASurinary tract,bladder,carcinoma,undifferentiated carcinomac.181C>Gp.Q61E0
14COSM46303TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.1031T>Gp.L344R0
15COSM532KRASurinary tract,bladder,carcinoma,adenocarcinomac.38G>Ap.G13D0
16COSM10709TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.722C>Gp.S241C0
17COSM45248TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.805A>Tp.S269C0
18COSM43963TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.396G>Cp.K132N0
19COSM11491TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.743G>Cp.R248P0
20COSM44525TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.709A>Gp.M237V0
21COSM10705TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.586C>Tp.R196*0
22COSM488HRASurinary tract,bladder,carcinoma,squamous cell carcinomac.37G>Tp.G13C0
23COSM520KRASurinary tract,bladder,carcinoma,adenocarcinomac.35G>Tp.G12V0
24COSM10738TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.542G>Ap.R181H0
25COSM10727TP53urinary tract,bladder,carcinoma,adenocarcinomac.438G>Ap.W146*0
26COSM45299TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.831T>Gp.C277W0
27COSM10719TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.811G>Ap.E271K0
28COSM45286TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.475G>Tp.A159S0
29COSM44451TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.874A>Gp.K292E0
30COSM44950TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.862A>Gp.N288D0
31COSM43660TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.719G>Tp.S240I0
32COSM45138TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.853G>Cp.E285Q0
33COSM43565TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.857A>Gp.E286G0
34COSM44091TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.746G>Ap.R249K0
35COSM6932TP53urinary tract,bladder,carcinoma,adenocarcinomac.733G>Ap.G245S0
36COSM43616TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.704A>Gp.N235S0
37COSM44117TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.775G>Ap.D259N0
38COSM44469TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.812A>Tp.E271V0
39COSM45284TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.813G>Ap.E271E0
40COSM19500CDH1urinary tract,bladder,carcinoma,squamous cell carcinomac.2537G>Cp.S846T0
41COSM10704TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.844C>Tp.R282W0
42COSM10654TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.637C>Tp.R213*0
43COSM44603TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.835G>Ap.G279R0
44COSM10801TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.404G>Ap.C135Y0
45COSM10728TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.839G>Ap.R280K0
46COSM44202TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.550G>Tp.D184Y0
47COSM10810TP53urinary tract,bladder,carcinoma,squamous cell carcinomac.725G>Tp.C242F0

Copy number variations for Bladder Cancer, Somatic from CNVD:

6 (show top 50)    (show all 98)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1147701110031964110037890Decreasing copy numberGSTM1Bladder cancer
2166601128900000185800000GainBladder cancer
3180511143699872161705044GainBladder cancer
43653417706889877170790LossBladder cancer
55177811130615965132678521LossBladder cancer
653648113151779632050223LossBladder cancer
758531116832305469297218GainBladder cancer
867850124546623958591220GainBladder cancer
9751361316000000114142980Copy numberBladder cancer
1079497137253413772746128GainBladder cancer
11807571397270228100084626GainBladder cancer
128134114101619009102408085LossBladder cancer
1383177141936485119446107LossBladder cancer
1487829147775064579747731LossBladder cancer
1588246148863275689467875GainBladder cancer
1689915151942735019427409LossBladder cancer
1796847159505288995403459LossBladder cancer
1897491161064779411795463GainBladder cancer
1998997162222123532532138GainBladder cancer
20101674164541378045607724GainBladder cancer
21101856164654829969323131LossBladder cancer
221030471659960676407032LossBladder cancer
23104499166954300470813070GainBladder cancer
241076471716495951725887LossBladder cancer
25109050172400000038100000GainBladder cancer
26109225172464192627576519GainBladder cancer
27112300173852126478444637GainBladder cancer
281181081775717197590863LossTP53Bladder cancer
2912174218467310796252GainBladder cancer
30122814186164314267432063LossBladder cancer
31126424191874953419294814GainBladder cancer
321271481927807312616127GainBladder cancer
33127869193785693563485510GainBladder cancer
3413567921195673012796508GainBladder cancer
351359592123437325126399586LossBladder cancer
361382312159948195160120757LossBladder cancer
371418502217249378242464793LossBladder cancer
3814658125123611751635693LossBladder cancer
3914719026096692361033726LossBladder cancer
4014728426208131062298660LossBladder cancer
4114816327446950579433LossBladder cancer
421503202987288110505097GainBladder cancer
4315097420157771456225GainBladder cancer
44151125201787022118440898GainBladder cancer
45151502202209337126036562GainBladder cancer
46152003202808159847163674GainBladder cancer
47154726204803350154958791GainBladder cancer
48156571206172775362175139GainBladder cancer
49158507213358185134132794GainBladder cancer
50160744221625959716597551LossBladder cancer

Expression for genes affiliated with Bladder Cancer, Somatic

About this section
Search GEO for disease gene expression data for Bladder Cancer, Somatic.

Pathways for genes affiliated with Bladder Cancer, Somatic

About this section

Pathways related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 61)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.3CDKN1A, TP53
210.3HRAS, KRAS, RB1
310.2CDKN2A, RB1, TP53
410.2ERBB2, HRAS, KRAS
510.2CDH1, ERBB2, HRAS
610.2CDKN1A, CDKN2A, TP53
7
Show member pathways
10.2HRAS, RB1, TP53, TSC1
810.2CDH1, HRAS, KRAS, TP53
910.1CDKN1A, HRAS, KRAS, TP53
1010.1FGF2, FGFR3, HRAS, KRAS
11
Show member pathways
10.1FGF2, FGFR3, HRAS, KRAS
1210.1FGF2, FGFR3, HRAS, KRAS
13
Show member pathways
10.1FGF2, FGFR3, HRAS, KRAS
14
Show member pathways
10.1CDKN1A, HRAS, TP53, TSC1
1510.1CDH1, CDKN1A, KRAS, TP53
1610.1CDKN1A, CDKN2A, RB1, TP53
17
Show member pathways
10.1CDKN1A, CDKN2A, RB1, TP53
1810.1CD44, CDKN1A, RB1, TP53
1910.1ERBB2, FGFR3, HRAS, KRAS, TP53
20
Show member pathways
10.1ERBB2, FGFR3, HRAS, KRAS, TP53
2110.1CDH1, KRAS, RB1, TP53, TSC1
22
Show member pathways
10.1ERBB2, FGFR3, KRAS, TP53, TSC1
23
Show member pathways
10.1CDH1, ERBB2, HRAS, KRAS, RB1
2410.1FGF2, FGFR3, HRAS, KRAS, TP53
25
Show member pathways
10.1CDKN1A, ERBB2, HRAS, KRAS, TP53
26
Show member pathways
10.0CDKN1A, CDKN2A, KRAS, TP53, TSC1
2710.0CDH1, CDKN1A, CDKN2A, RB1, TP53
2810.0ERBB2, FGF2, FGFR3, HRAS, KRAS
2910.0CDKN1A, CDKN2A, MKI67, RB1, TP53
3010.0CDKN1A, CDKN2A, HRAS, KRAS, RB1, TP53
3110.0CDKN1A, CDKN2A, HRAS, KRAS, RB1, TP53
32
Show member pathways
10.0CD44, CDKN1A, CDKN2A, ERBB2, TP53
3310.0CD44, EZH2, FGF2, FGFR3, GNL3
34
Show member pathways
10.0CDH1, CDKN1A, ERBB2, HRAS, KRAS, TP53
35
Show member pathways
9.9CDKN1A, ERBB2, FGF2, FGFR3, HRAS, KRAS
36
Show member pathways
9.9CDH1, FGF2, FGFR3, HRAS, KRAS, RASSF1
379.9CD44, CDKN1A, CDKN2A, HRAS, RB1, TP53
38
Show member pathways
9.9CDKN1A, ERBB2, FGFR3, KRAS, RB1, TP53
399.9CDKN1A, CDKN2A, HRAS, KRAS, RB1, TP53
409.9CDKN1A, ERBB2, EZH2, FGF2, KRAS, TP53
41
Show member pathways
9.9CDKN1A, CDKN2A, ERBB2, HRAS, KRAS, RB1
429.9CDKN1A, FGF2, FGFR3, HRAS, KRAS, TP53
43
Show member pathways
9.8CDH1, CDKN1A, DAPK1, FGF2, FGFR3, HRAS
449.8CD44, CDKN1A, ERBB2, FGF2, HRAS, KRAS
45
Show member pathways
9.8CDKN1A, ERBB2, FGF2, FGFR3, HRAS, KRAS
469.5CD44, CDKN1A, CDKN2A, ERBB2, EZH2, FGFR3
47
Show member pathways
9.5CDH1, CDKN1A, CDKN2A, ERBB2, FGF2, FGFR3
48
Show member pathways
9.5CDH1, CDKN1A, CDKN2A, ERBB2, FGF2, HRAS
499.4CDH1, CDKN1A, CDKN2A, DAPK1, ERBB2, FGFR3
509.4CDH1, CDKN1A, CDKN2A, DAPK1, ERBB2, FGF2

GO Terms for genes affiliated with Bladder Cancer, Somatic

About this section

Cellular components related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmGO:00057378.9CD44, CDH1, CDKN1A, CDKN2A, DAPK1, ERBB2

Biological processes related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1striated muscle cell differentiationGO:005114610.9KRAS, RB1
2positive regulation of cellular senescenceGO:200077410.9CDKN2A, KRAS
3regulation of phosphatidylinositol 3-kinase signalingGO:001406610.8ERBB2, FGF2, FGFR3
4cellular senescenceGO:009039810.8CDKN1A, CDKN2A, HRAS
5replicative senescenceGO:009039910.8CDKN1A, CDKN2A, TP53
6ERBB2 signaling pathwayGO:003812810.7ERBB2, HRAS, KRAS
7negative regulation of G1/S transition of mitotic cell cycleGO:200013410.7CDKN1A, EZH2, RB1
8intrinsic apoptotic signaling pathwayGO:009719310.6CDKN1A, HRAS, TP53
9positive regulation of protein phosphorylationGO:000193410.6ERBB2, FGF2, HRAS, KRAS
10negative regulation of gene expressionGO:001062910.5CDKN1A, EZH2, HRAS, RB1
11positive regulation of epithelial cell proliferationGO:005067910.4ERBB2, FGF2, HRAS
12MAPK cascadeGO:000016510.4ERBB2, FGF2, FGFR3, HRAS, KRAS
13positive regulation of MAP kinase activityGO:004340610.3ERBB2, EZH2, FGF2, HRAS, KRAS
14cell cycle arrestGO:000705010.3CDKN1A, CDKN2A, HRAS, RASSF1, RB1, TP53
15regulation of cell cycleGO:005172610.3CDKN1A, FGF2, RB1, TSC1
16positive regulation of gene expressionGO:001062810.1ERBB2, FGF2, HRAS, KRAS, TP53
17cell proliferationGO:000828310.1ERBB2, GNL3, HRAS, MKI67, TP53
18positive regulation of ERK1 and ERK2 cascadeGO:007037410.1CD44, FGF2, FGFR3, HRAS
19Ras protein signal transductionGO:00072659.7CDKN1A, CDKN2A, FGF2, HRAS, KRAS, RASSF1
20negative regulation of cell proliferationGO:00082859.6CDKN1A, CDKN2A, FGF2, HRAS, RB1, TP53

Molecular functions related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486111.0CDKN1A, CDKN2A
2phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.9ERBB2, FGF2, FGFR3
3protein bindingGO:00055158.6CD44, CDH1, CDKN1A, CDKN2A, DAPK1, ERBB2

Sources for Bladder Cancer, Somatic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet